Annual Accounts Receivable
$264.93 M
+$58.48 M+28.33%
December 31, 2024
Summary
- As of March 10, 2025, APLS annual accounts receivable is $264.93 million, with the most recent change of +$58.48 million (+28.33%) on December 31, 2024.
- During the last 3 years, APLS annual accounts receivable has risen by +$254.82 million (+2522.25%).
- APLS annual accounts receivable is now at all-time high.
Performance
APLS Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$264.93 M
-$14.09 M-5.05%
December 31, 2024
Summary
- As of March 10, 2025, APLS quarterly accounts receivable is $264.93 million, with the most recent change of -$14.09 million (-5.05%) on December 31, 2024.
- Over the past year, APLS quarterly accounts receivable has stayed the same.
- APLS quarterly accounts receivable is now -12.98% below its all-time high of $304.43 million, reached on June 30, 2024.
Performance
APLS Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
APLS Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +28.3% | 0.0% |
| 3 y3 years | +2522.3% | +2522.3% |
| 5 y5 years | - | +2522.3% |
APLS Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +3328.6% | -13.0% | +4085.2% |
| 5 y | 5-year | at high | -100.0% | -13.0% | -100.0% |
| alltime | all time | at high | -100.0% | -13.0% | -100.0% |
Apellis Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $264.93 M(+28.3%) | $264.93 M(-5.0%) |
| Sep 2024 | - | $279.01 M(-8.4%) |
| Jun 2024 | - | $304.43 M(+13.7%) |
| Mar 2024 | - | $267.84 M(+29.7%) |
| Dec 2023 | $206.44 M(+2571.7%) | $206.44 M(+22.0%) |
| Sep 2023 | - | $169.26 M(+52.6%) |
| Jun 2023 | - | $110.91 M(+252.0%) |
| Mar 2023 | - | $31.50 M(+307.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $7.73 M(-23.5%) | $7.73 M(-4.5%) |
| Sep 2022 | - | $8.09 M(+7.6%) |
| Jun 2022 | - | $7.52 M(+18.8%) |
| Mar 2022 | - | $6.33 M(-37.3%) |
| Dec 2021 | $10.10 M(>+9900.0%) | $10.10 M(+186.9%) |
| Sep 2021 | - | $3.52 M(+389.8%) |
| Jun 2021 | - | $719.00 K(>+9900.0%) |
| Dec 2020 | $0.00 | $0.00 |
FAQ
- What is Apellis Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual accounts receivable year-on-year change?
- What is Apellis Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Apellis Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of APLS is $264.93 M
What is the all time high annual accounts receivable for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual accounts receivable is $264.93 M
What is Apellis Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, APLS annual accounts receivable has changed by +$58.48 M (+28.33%)
What is Apellis Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of APLS is $264.93 M
What is the all time high quarterly accounts receivable for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly accounts receivable is $304.43 M
What is Apellis Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, APLS quarterly accounts receivable has changed by $0.00 (0.00%)